NGEmzor Pharmaceutical Industries has raised N26.7 billion ($19.8 million) through a five-year fixed-rate bond on the FMDQ Group Exchange to fund its expansion and the construction of West Africa’s first full-scale anti-malarial Active Pharmaceutical Ingredient (API) manufacturing facility. This is part of a larger N40 billion bond issuance program and follows strong investor interest, with the bond being oversubscribed. The funds will support working capital, increase manufacturing capacity, and complete the API plant. Emzor aims to transition from a local medicine manufacturer to a producer of essential pharmaceutical inputs, reducing Nigeria’s reliance on imported drugs and raw materials. The company was founded in 1977 and now produces over 120 medicines across 16 therapeutic areas. Local API production could enhance supply chain resilience, reduce exposure to global market fluctuations, and improve access to critical pharmaceutical inputs in Nigeria.
Bias read (Center): The article provides a balanced overview of Emzor's financial activities and their economic implications without overtly favoring any political stance. It focuses on corporate actions and their impact on national pharmaceutical self-sufficiency, avoiding direct political commentary or biased framing
